AMAhinoa Fernández Moreno

Ahinoa Fernández Moreno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahinoa Fernández Moreno has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of a Shotgun Metagenomics Approach for Detection of ESBL- and/or Carbapenemase-Producing Enterobacterales in Culture Negative Patients Recovered from Acute Leukemia

    by Pilar Lumbreras-Iglesias, Carlos Sabater, Ainhoa Fernández Moreno, Paula López de Ugarriza, Ana Fernández-Verdugo, Abelardo Margolles, María Rosario Rodicio, Teresa Bernal, Javier Fernández

    Patients diagnosed with acute leukemia (AL) have a weakened immune system. Infections acquired by these patients are cause for concern and especially worrisome when Gram-negative multidrug-resistant (MDR) bacteria are involved, as they are difficult to treat, especially in the case of ESBL- and/or carbapenemase-producing Enterobacterales. Culture-based approaches have been relied on over the past decades as the method of choice for the early detection of gut colonization by MDR Gram-negative bacteria. However, various studies have indicated its limited sensitivity, underlining the need for new screening procedures in onco-hematological patients. Here, we evaluated a shotgun metagenomics approach to detect ESBL- and/or carbapenemase-producing Enterobacterales in the gut of 28 patients who had recovered from AL, which were previously colonized by these bacteria but cured at the time of sampling, as judged by culture-based methods. No ESBL or carbapenemase determinants were detected among the many resistance genes found by the metagenomics approach, supporting that patients were truly decolonized, with considerable consequences for their future clinical management. Due to the relatively low number of patients available for the present investigation, further studies should be conducted to support the utility and applicability of metagenomics for the routine screening of MDR bacteria in onco-hematological patients.


  • Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    by Álvaro Díaz-González, Manuel Hernández-Guerra, Indhira Pérez-Medrano, Víctor Sapena, Mar Riveiro-Barciela, Ana Barreira-Díaz, Elena Gómez, Rosa M Morillas, María Del Barrio, Laia Escudé, et al.

    Background and Aims: In patients with non-severe acute or chronic autoimmune hepatitis (AIH) without cirrhosis, clinical practice guidelines recommend indistinct use of prednisone or budesonide. However, budesonide is infrequently used in clinical practice. We aimed to describe its use and compare its efficacy and safety with prednisone as first-line options. Approach and Results: This was a retrospective, multicenter study of 105 naive AIH patients treated with budesonide as the first-line drug. The control group included 276 patients treated with prednisone. Efficacy was assessed using logistic regression and validated using inverse probability of treatment weighting propensity score. The median time to biochemical response (BR) was 3.1 months in patients treated with budesonide and 4.9 months in those with prednisone. The BR rate was significantly higher in patients treated with prednisone (87% vs. 49% of patients with budesonide, p < 0.001). The probability of achieving BR, assessed using the inverse probability of treatment weighting propensity score, was significantly lower in the budesonide group (OR = 0.20; 95% CI: 0.11–0.38) at any time during follow-up, and at 6 (OR = 0.51; 95% CI: 0.29–0.89) and 12 months after starting treatment (0.41; 95% CI: 0.23–0.73). In patients with transaminases p = 0.047). Conclusions: In the real-life setting, the use of budesonide as first-line treatment is low, and it is generally prescribed to patients with perceived less disease activity. Budesonide was inferior to prednisone as a first-line drug but was associated with fewer side effects.


  • Open Access

    The Value of Adding Surveillance Cultures to Fluoroquinolone Prophylaxis in the Management of Multiresistant Gram Negative Bacterial Infections in Acute Myeloid Leukemia

    by Christelle Castañón, Ahinoa Fernández Moreno, Ana María Fernández Verdugo, Javier Fernández, Carmen Martínez Ortega, Miguel Alaguero, Concepción Nicolás, Laura Vilorio Marqués, Teresa Bernal

    Multidrug resistant Gram-Negative Bacterial Infections (MR-GNBI) are an increasing cause of mortality in acute myeloid leukemia (AML), compromising the success of antineoplastic therapy. We prospectively explored a novel strategy, including mandatory fluoroquinolone prophylaxis, weekly surveillance cultures (SC) and targeted antimicrobial therapy for febrile neutropenia, aimed to reduce infectious mortality due to MR-GNBI. Over 146 cycles of chemotherapy, cumulative incidence of colonization was 50%. Half of the colonizations occurred in the consolidation phase of treatment. Application of this strategy led to a significant reduction in the incidence of GNB and carbapenemase-producing Klebisella pneumoniae (cpKp) species, resulting in a reduction of infectious mortality (HR 0.35 [95%, CI 0.13–0.96], p = 0.042). In multivariate analysis, fluroquinolone prophylaxis in addition to SC was associated with improved survival (OR 0.55 [95% CI 0.38–0.79], p = 0.001). Targeted therapy for colonized patients did not overcome the risk of death once cpKp or XDR Pseudomonas aeruginosa infections were developed. Mortality rate after transplant was similar between colonized and not colonized patients. However only 9% of transplanted patients were colonized by cpkp. In conclusion, colonization is a common phenomenon, not limited to the induction phase. This strategy reduces infectious mortality by lowering the global incidence of GN infections and the spread of resistant species.


  • Intravenous Immunoglobulin Replacement Therapy in Solid Organ Transplantation with Severe Infections and Secondary Antibody Deficiency

    by Javier Carbone, Juan Fernandez-Yañez, Judith Montanchez, Eduardo Zatarain, Joaquin Navarro, Maria Rodriguez-Ferrero, Fernando Anaya, Magdalena Salcedo, Ainhoa Fernandez, Patricia Muñoz, et al.

    Background Secondary antibody deficiency is a risk factor of severe infection in solid organ transplantation. Very few studies have previously evaluated the potential role of IgG replacement in solid organ recipients with IgG hypogammaglobulinemia (HGG) at the time of a severe infectious complication. We evaluated the impact of therapeutic intervention of intravenous immunoglobulin (IVIG) in solid organ recipients with severe infections and HGG on clinical outcomes. Methods Retrospective analysis of prospectively collected data of 60 patients in a single center. All patients were hospitalized because of severe infections or developed a severe infection during a hospitalization in the post-transplantation period (June 2015-June 2017) and were found to have HGG (serum IgG750 mg/dL) and 28 patients were treated with only conventional antimicrobial therapy. IVIG was administered at a dose of 300-400 mg/kg/month. Clinical outcome was the incidence of new infectious complications and deadly infections during a 6-month follow up. Results Distribution of solid organ recipients was as follows: Heart 37, liver 10, kidney 13. The incidente of re-infection was significantly higher in patients with HGG that were not treated with IVIG as compared with IVIG-treated patients (78.6% vs 28.1%, two-sided chi-square test pInstituto de Salud Carlos III. Project FIS Clinical Trial EC11084. With participation of FEDER funds. A way of making Europe.